Abstract Macrophages are unique innate immune cells that play an integral role in the defense of the host by virtue of their ability to recognize, engulf, and kill pathogens while sending out danger signals via cytokines to recruit and activate inflammatory cells. It is becoming increasingly clear that purinergic signaling events are essential components of the macrophage response to pathogen challenges and disorders such as sepsis may be, at least in part, regulated by these important sensors. The activation of the P2X 7 receptor is a powerful event in the regulation of the caspase-1 inflammasome. We provide evidence that the inflammasome activation requires "priming" of macrophages prior to ATP activation of the P2X 7 R. Inhibition of the inflammasome activation by the tyrosine kinase inhibitor, AG126, suggests regulation by phosphorylation. Finally, the P2X 7 R may also be activated by other elements of the host response such as the antimicrobial peptide LL-37, which adds a new, physiologically relevant agonist to the P2X 7 R pathway. Therapeutic approaches to inflammation and sepsis will certainly be enhanced by an increased understanding of how purinergic receptors modulate the inflammasomes.
Introduction
Purinergic receptors of the P2X 7 form have revolutionized our concepts about the mechanisms involved in the activation of caspase-1. The ability of exogenous pathogen-associated molecular patterns, such as lipopolysaccharide (LPS), to induce the processing and release of interleukin (IL)-1β has been part of the IL-1β literature since IL-1's discovery as endogenous pyrogen [1, 2] . However, the relatively recent recognition of the marked potentiation of the LPS effect by P2X 7 receptor activation has transformed our understanding of host cells' ability to sense danger and respond. In this review we will focus on the role of P2X 7 receptor activation in the modulation of monocyte and macrophage caspase-1 activation.
Human monocytes express P2X 7 receptors
Human monocytes express four-to fivefold higher levels of P2X 7 receptors than lymphocytes when analyzed by flow cytometry [3] . Furthermore, monocytes further increase the numbers of surface receptors as they differentiate into macrophages [4] . Flow cytometry of fresh human monocytes, gating on the CD14 monocyte marker, reveals that both baseline and LPS-treated monocytes have similar levels of surface expressed P2X 7 [5] confirming previous data showing expression on 1-day-old monocytes [6] . The size of monocyte P2X 7 R is 75 kDa by immunoblotting [7] but the detection is weak. In fact we have seen a 55-kDa P2X 7 form when immunoblotting freshly harvested blood monocytes but this may represent a cleavage artifact from monocyte proteases [5] .
Fresh monocytes are potent releasers of mature IL-1β upon endotoxin activation when given high-dose LPS. LPS at 10 μg/ml will induce the release of mature IL-1β within 2-4 h of stimulation. However, low-dose LPS (e.g., 1 ng/ml) releases only minimal amounts of mature IL-1β but produces near maximum quantities of the precursor form of IL-1β, the 31-kDa proIL-1β.
Monocytes induced to produce the 31-kDa proIL-1β can be induced to release large amounts of processed 17-kDa mature IL-1β with the addition of the P2X 7 receptor agonist, ATP [8] [9] [10] [11] . Monocytes primed for 3 h with 1 ng/ml of LPS and then given a 30-min pulse with 5 mM ATP release 10-to 20-fold higher amounts of processed, mature IL-1β than monocytes treated with high-dose LPS alone [5] . This ATPmediated effect is blocked by oATP. Thus, it is clear that the monocyte P2X 7 receptors are functional.
Priming required for ATP-induced caspase-1 activation P2X 7 activation: requirement for priming This LPS priming step is necessary as ATP stimulation alone will not induce IL-1β release. Indeed LPS priming is needed to induce sufficient intracellular proIL-1β substrate for the ATPinduced caspase-1 activation. However, substrate generation is not the only function of the priming step. This fact is derived from studies with the other well-recognized substrate of active caspase-1, IL-18 [12] . Fortunately for the study of priming's role in the ATP-mediated activation of caspase-1, IL-18 is constitutively present in fresh monocytes. Thus, if priming were simply a means to generate substrate for the P2X 7 -mediated caspase-1 activation, then one would anticipate that ATP stimulation alone would generate active processed IL-18. This is not the case. As outlined in Fig. 1a , although fresh human monocytes contain preformed intracellular proIL-18, they release no processed IL-18 unless preactivated, in this case with LPS.
Time of priming event As early as 15-30 min after LPS priming, presumably too early for significant new proteins synthesis, monocytes respond to ATP inducing near maximum processing and release of mature IL-18. The exact processes involved in the priming event remain poorly understood.
P2X 7 activation inhibited by tyrphostin AG126
Attempting to characterize the signaling events that are induced by ATP, we previously tested a battery of kinase inhibitors for their ability to block ATP-induced activation of IL-1β processing by primed monocytes [5] . As shown in Table 1 , one tyrosine kinase inhibitor, AG126, a synthetic homologue of erbstatin, potently inhibits the ATP-induced caspase-1 activation event even when given after the LPSinduced priming [5, 13] . This finding is particularly intriguing since it had been shown that AG126 can prevent sepsis-induced death in a murine model of sepsis and can block chronic inflammation [14, 15] . In this same vein, we have recently noted that apoptosis of splenic B lymphocytes is characteristic of the murine response to sepsis and that this apoptosis is in part dependent upon caspase-1 activation since it is absent in caspase-1 knockout animals [16] . Consistent with the possibility that the sepsis protection of AG126 is due to its inhibition of ATP-induced caspase-1 Fig. 1 Caspase-1-dependent processing and release of IL-1β and IL-18. a "Priming" required of monocytes. Fresh human monocytes purified by CD14 magnetic beads (n=3) cultured at 10 6 cells/ml induce abundant levels of intracellular proIL-1β (lysed at 10 6 cells/ml) in response to lipopolysaccharide (LPS) but require additional stimulation with ATP to process and release IL-1β. In contrast, these same monocytes constitutively contain IL-18, but they still require LPS priming for the ATP effect on processing and release. b "Priming" blunted in alveolar macrophages. Human lung alveolar macrophages from the same individuals in a obtained by bronchoalveolar lavage show blunted response to LPS priming for ATP-induced processing and release of both IL-1β and IL-18 (representative experiment). However, macrophages have similar levels of induced intracellular IL-1β and almost log-fold higher concentrations of intracellular IL-18 activity, we have shown that intraperitoneal AG126 can also prevent splenic cell apoptosis in murine sepsis as well (Fig. 2) . Although there is no evidence directly connecting AG126 to the P2X 7 receptor, recent work by Shemon et al. further supports the notion that the P2X 7 receptor functions via tyrosine kinase activation [17] . Furthermore, they show that B lymphocytes may be targeted via their own P2X 7 receptors. Of note, however, Shemon et al.'s protein tyrosine kinase inhibitor works on the extracellular side of the P2X 7 receptor and therefore may function by competing with ATP at the extracellular binding site. There is a highly conserved tyrosine residue in the carboxy terminus of the P2X 7 receptor near the second transmembrane region which appears to affect its channel function [18] . The role of AG126 in this regard is still unknown. We have unpublished data that AG126 can slow the spontaneous activation of lysed THP-1 caspase-1 that was first described by Miller et al. [19] . However, this does not prove a connection to the P2X 7 R nor whether the AG126 effect is intracellular or extracellular. Since it is not known if this P2X 7 tyrosine is the target of AG126, future investigations into the target(s) of AG126 will be of considerable interest for therapeutics.
Macrophages less responsive than monocytes to P2X 7 agonists
Alveolar macrophages are frontline pathogen sensors that live in the alveolar space where they encounter inhaled particulates and pathogens. These macrophages rapidly engulf pathogens and either kill them or send out cytokine responses that recruit assistance from neutrophils and lymphocytes. It is believed that each alveolus contains numerous macrophages [20] . It is remarkable that in general these macrophages are able to deal with the massive challenge of eliminating inhaled particulate and pathogens without causing untoward inflammation. Importantly, P2X 7 receptor function has been linked to the ability of macrophages to handle pathogens. For example, P2X 7 receptor activation induces macrophages to kill one of the most lung-adapted pathogens, i.e., intracellular Mycobacterium [21] . Fig. 2 Tyrphostin AG126 protects mice from sepsis mortality and splenic cell apoptosis. Since AG126 blocks the ATP-induced (i.e., P2X 7 -mediated) processing of IL-1β and IL-18, we tested AG126 for its ability to inhibit E. coli-induced mortality (top) and splenic apoptosis at 24 h post challenge (bottom). In the survival experiment, mice were pretreated with AG126 or dimethyl sulfoxide (DMSO) control i.p. followed by live E. coli 10 8 cfu per animal and followed for survival Macrophages derive predominantly from circulating blood monocytes which are short-lived descendants of bone marrow precursors that circulate for 24-48 h before taking up tissue residence and differentiating into macrophages or being eliminated by programmed cell death [22] [23] [24] . In this context, we have long been interested in the relative ability of lung macrophages versus blood monocytes to respond to pathogen stimulation. Alveolar macrophages do sense bacterial endotoxins. For example, normal human lung macrophages stimulated with 10 μg/ml of E. coli LPS release significant amounts of tumor necrosis factor (TNF) but surprisingly little IL-1β [25] . However, fresh blood monocytes given the same LPS challenge are excellent producers of IL-1β but release more limited quantities of TNF [25, 26] . Importantly, the relative ability of alveolar macrophages to produce IL-18 and IL-1β is intact. Alveolar macrophage intracellular proIL-1β is similar to that of monocytes. Intracellular proIL-18 is even more abundant in alveolar macrophages and is present constitutively, i.e., without priming (Fig. 1b) . Nevertheless, macrophages seem to lack some of the upstream events necessary to activate the P2X 7 receptor-mediated activation of the inflammasome as evidenced by the minimum response to priming and ATP. This monocyte/macrophage difference in IL-1β processing and release remains poorly understood despite more that two decades of recognition. It suggests additional regulatory elements that remain to be characterized.
Alternative means of activating P2X 7 : protegrin and cathelicidin ATP's effect on the P2X 7 receptor is maximum at relatively high concentrations of extracellular ATP. Concentrations in the 1-5 mM range, i.e., equivalent to the intracellular concentration of ATP, are typically used experimentally for caspase-1 activation experiments [9, 10, 27] . These high concentration requirements for ATP raise the issue about whether these levels are achievable during physiological regulation of the P2X 7 receptor. In the microenvironment of cell compartments it is possible that local release of ATP from adjacent cells (e.g., platelets [28] ) or even autocrine release induced by activating agents such as LPS [29, 30] may provide ATP concentrations that approach the 1-5 mM range. However, much remains to be uncovered about how the P2X 7 receptors work under normal physiological conditions.
In the context of IL-1β/IL-18 processing and release, ATP induces the release of potassium, an event that is dependent upon pore formation and loss of intracellular vs extracellular potassium gradients. In a yet to be fully understood mechanism, ATP-induced loss of intracellular potassium induces the activation of the NALP3 (NLRP3) inflammasome followed by the rapid activation of caspase-1 and the processing and release of IL-1β and IL-18 [31] . Blocking the potassium efflux by exogenous potassium, however, blocks the ability of ATP to induce IL-1β/IL-18 processing [9, 13] . Thus, a major outcome of the P2X 7 receptor activation event appears to be the induction of pores that allow potassium escape. Recently, the identification of pannexin-1 as a P2X 7 receptor-activated pore follows this theme [32] . Perregaux and Gabel have shown that several agents that are capable of inducing pores independently of P2X 7 receptors can induce the activation of caspase-1 and IL-1β processing and release [9] . The antibiotic ionophore nigericin induces inflammasome activation by virtue of its ability to efflux potassium from cells [33] . More recently, the role of pannexin-1 in the activation of caspase-1 has further expanded. Pelegrin and Surprenant have shown that inhibition of pannexin-1 can block caspase-1 activation even in the presence of potassium efflux suggesting that it functions downstream of potassium's efflux [34] . Interestingly, pannexin-1 may also function to bring PAMPs into the cytosol for pathogen sensing [35] .
Cathelicidin as pore inducer If ionophores can induce inflammasome activation by inducing potassium efflux, then antimicrobial peptides might do the same. Antimicrobial peptides are particularly interesting since their release is a physiologic response of the host to pathogen-induced TLR and NLR signals [36, 37] . This relevance was confirmed with protegrins, which are neutrophil antimicrobial products that when applied to LPS-activated human monocytes induce the rapid processing and release of IL-1β [38] . Akin to the ionophore nigericin's mechanism, the protegrin function was shown to be due to their pore-forming function because eliminating the efflux of potassium prevents the inflammasome activation event [38] .
In an effort to mimic the protegrin function, we recently applied the same reasoning to another important antimicrobial peptide cathelicidin (LL-37), which also functions at least in part by virtue of membrane permeabilization and has been shown to be produced in the lung by epithelial cells [30, [39] [40] [41] . However, to our surprise it appears that LL-37, while certainly capable of inducing pore formation, functions at least in part via its ability to modulate the P2X 7 receptor.
Although LL-37 is capable of enhancing IL-1β processing and release by LPS-primed monocytes, it actually inhibits LPS's effect when added simultaneously. Presumably, this inhibition is due to the ability of LL-37 to bind to LPS and prevent its interaction with LBP and CD14 [42] . However, when added to preactivated monocytes, i.e., monocytes that are induced to express intracellular proIL-1β, LL-37 significantly augments the release of processed IL-1β, the signature of inflammasome activation. Importantly, LL-37 does not alter the release of IL-8, an event independent of inflammasome activation [30] .
Although LL-37 does induce pore formation as evidenced by the uptake of the fluorescent nucleic acid dye, YO-PRO-1, and the release of intracellular ATP, it appears that LL-37 is directly activating P2X 7 receptors. Inhibitors of P2X 7 receptor function were able to interfere with the LL-37-mediated inflammasome activation. KN04, KN62, and oxidized ATP all inhibited IL-1β processing and release induced by LL-37 in a dose-response fashion. This direct inhibition of the P2X 7 receptor suggests that LL-37 works at least in part via activation of this purinergic receptor. Furthermore, oxidized ATP significantly inhibits the pore formation. However, this effect does not appear to be due to LL-37-mediated release of endogenous ATP. First of all, the concentration of ATP released in response to LL-37 is in the 100-200 nM range, well below the mM range needed for exogenously added ATP. Secondly, the addition of apyrase to the LL-37-stimulated cells does not block the IL-1β processing events but completely inhibits 5 mM ATP that has been exogenously added [30] . Thus, it appears that LL-37 can activate P2X 7 receptors by a mechanism that is independent of the release of endogenous ATP (see Fig. 3 for review of potential mechanisms of the LL-37 effect). Regardless of the exact mechanism though, it appears that specific antimicrobial peptides may have a dual function by linking IL-1β release to its direct effects on bacterial killing.
Summary
Macrophages are unique innate immune cells that play an integral role in the defense of the host by virtue of their ability to recognize, engulf, and kill pathogens while sending out danger signals to recruit additional cells to the battle. It is becoming increasingly clear that purinergic signaling events are essential components of the macrophage response to pathogen challenges and that disorders such as sepsis may be, at least in part, regulated by these important sensors. The activation of the P2X 7 receptor is a powerful event in the regulation of the caspase-1 inflammasome and this receptor may be activated by other elements of the host response such as the antimicrobial peptide LL-37. Our therapeutic possibilities will certainly Fig. 3 Schematic of potential mechanism of LL-37 interaction with P2X 7 receptor. Shown schematically are the potential mechanisms whereby the antimicrobial peptide, LL-37 (shown as an alpha helix), may activate the P2X 7 receptor and induce caspase-1 activation (numbered 1-3) . In process number 1, LL-37, via its cationic nature generates a transmembrane pore that allows potassium (K + ) to efflux from the cytosol. Low intracellular potassium results in inflammasome assembly (not shown) and hence caspase-1 activation; in number 2, LL-37 directly interacts with the P2X 7 receptor inducing a tyrosine phosphorylation event that is critical to the generation of a pannexin-1 pore that either allows potassium efflux (shown) or triggers a potassium-independent activation event [34] ; finally possibility number 3 involves the P2X 7 receptor indirectly by means of an LL-37 pore that allows the activation of the P2X 7 receptor via autocrine ATP. AG126 is shown as a putative inhibitor either of the critical phosphorylation of the carboxy-terminal tyrosine 343 [18] of the P2X 7 receptor or of its extracellular ATP binding site be enhanced by increase understanding of the regulation of the purinergically regulated pores.
